^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Small Intestinal Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
…the NCCN Panel recommends either pembrolizumab or nivolumab, with or without ipilimumab, as second-line treatment options for dMMR/MSI-H advanced SBA.
